Embecta (NASDAQ:EMBC) Updates FY 2025 Earnings Guidance

Embecta (NASDAQ:EMBC) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 2.700-2.900 for the period, compared to the consensus EPS estimate of 2.810. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Embecta Stock Performance

Embecta stock opened at $17.42 on Friday. The stock has a 50-day simple moving average of $19.65 and a 200-day simple moving average of $16.53. The company has a market capitalization of $1.01 billion, a P/E ratio of 17.42, a PEG ratio of 0.95 and a beta of 1.20. Embecta has a fifty-two week low of $9.93 and a fifty-two week high of $21.48.

Embecta (NASDAQ:EMBC) last announced its earnings results on Thursday, February 6th. The company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. As a group, analysts forecast that Embecta will post 2.87 earnings per share for the current year.

Embecta Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 14th. Investors of record on Friday, February 28th will be issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date is Friday, February 28th. Embecta’s dividend payout ratio is currently 60.00%.

Analyst Upgrades and Downgrades

EMBC has been the subject of a number of recent research reports. Morgan Stanley raised Embecta from an “underweight” rating to an “equal weight” rating and increased their price objective for the stock from $13.00 to $20.00 in a research report on Monday, December 2nd. BTIG Research raised Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price target for the company in a report on Wednesday, November 27th.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.